Emergent BioSolutions (EBS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Definitive additional proxy materials were filed in connection with the upcoming annual meeting scheduled for April 29, 2026.
The annual meeting will be held virtually, allowing shareholders to participate online.
Voting matters and shareholder proposals
Shareholders are invited to attend and vote at the virtual annual meeting on April 29, 2026.
Shareholder rights and capital structure
No filing fee was required for this proxy material submission, indicating routine annual meeting matters.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Emergent BioSolutions
- Q2 2026 saw strong MCM growth but a $191.3M NARCAN® impairment drove a $180.2M net loss.EBS
Q2 2026 - Turnaround delivers strong EBITDA, innovation, and global growth in biodefense and opioid solutions.EBSGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Turnaround delivers strong Q1 2026 results, with growth from innovation and global expansion.EBSJefferies Global Healthcare Conference 2026
- Q1 2026 revenue beat guidance but fell 30% year-over-year; liquidity and outlook remain strong.EBSQ1 2026
- Strong financial turnaround, all proposals approved, and growth-focused strategies outlined.EBSAGM 2026
- Annual meeting on April 29, 2026, with proxy voting available for eligible shareholders.EBSProxy filing
- Approval is sought for a new equity plan to support ongoing turnaround and talent retention.EBSProxy filing
- Annual meeting on April 29, 2026; eligible shareholders urged to vote by proxy.EBSProxy filing
- Q3 2024 net income jumped 144% and adjusted EBITDA rose 432% as guidance was raised.EBSQ3 2024